Skip to content
10-Q

Quarterly Report

AYTU BIOPHARMA, INC AYTU

0001437749-25-016833

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · May 1, 2025 6.17M sh
Long Term Debt Q3 2025 · Mar 31, 2025 $9.54M
Cash And Equivalents Q3 2025 · Mar 31, 2025 $18.17M
Cash And Equivalents Q3 2025 · Jun 30, 2024 $20.01M
Current Liabilities Q3 2025 · Mar 31, 2025 $70.71M
Current Liabilities Q3 2025 · Jun 30, 2024 $62.23M
Current Assets Q3 2025 · Mar 31, 2025 $72.51M
Current Assets Q3 2025 · Jun 30, 2024 $61.89M
Total Assets Q3 2025 · Mar 31, 2025 $124.2M
Total Assets Q3 2025 · Jun 30, 2024 $118.1M
Shares Diluted Q3 2025 · Mar 31, 2024 5.53M sh
Shares Diluted Q3 2025 · Mar 31, 2024 5.51M sh
Operating Cash Flow Q3 2025 · Mar 31, 2024 −$600K
Stockholders Equity Q3 2025 · Mar 31, 2024 $30.78M
Stockholders Equity Q3 2025 · Dec 31, 2023 $32.85M
Stockholders Equity Q3 2025 · Sep 30, 2023 $32.17M
Stockholders Equity Q3 2025 · Jun 30, 2023 $39.36M
Eps Diluted Q3 2025 · Mar 31, 2024 −$0.52
Eps Diluted Q3 2025 · Mar 31, 2024 −$2.04
Eps Basic Q3 2025 · Mar 31, 2024 −$0.52
Eps Basic Q3 2025 · Mar 31, 2024 −$2.04
Rd Expense restated Q3 2025 · Mar 31, 2024 $611K
Rd Expense restated Q3 2025 · Mar 31, 2024 $1.73M
Net Income Q3 2025 · Mar 31, 2024 −$2.89M
Net Income Q3 2025 · Mar 31, 2024 −$11.23M
Net Income Q3 2025 · Dec 31, 2023 −$220K
Net Income Q3 2025 · Sep 30, 2023 −$8.12M
Operating Income restated Q3 2025 · Mar 31, 2024 −$1.6M
Operating Income restated Q3 2025 · Mar 31, 2024 $682K
Gross Profit restated Q3 2025 · Mar 31, 2024 $10.36M
Gross Profit restated Q3 2025 · Mar 31, 2024 $38M
Revenue restated Q3 2025 · Mar 31, 2024 $14.03M
Revenue restated Q3 2025 · Mar 31, 2024 $50.59M